Is Ambien (Zolpidem) on the Beers Criteria?
Yes, Ambien (zolpidem) is explicitly listed on the 2019 American Geriatrics Society Beers Criteria as a potentially inappropriate medication for older adults and should generally be avoided in this population. 1
Classification and Recommendation
Zolpidem is categorized as a nonbenzodiazepine hypnotic ("Z-drug") that appears on the Beers Criteria list of medications that are potentially inappropriate in most older adults. 1
The AGS Beers Criteria recommends avoiding nonbenzodiazepine hypnotics in older adults due to their unfavorable balance of benefits versus harms, including increased risk of adverse events. 2
Key Safety Concerns in Elderly Patients
The primary rationale for inclusion on the Beers Criteria includes:
Increased fall risk: Multiple studies demonstrate that zolpidem exposure, particularly in elderly patients, significantly increases fall risk in both inpatient and outpatient settings. 2
CNS depression and cognitive impairment: Zolpidem acts as a GABA-A receptor positive modulator, causing CNS depression that can lead to decreased alertness, impaired psychomotor performance, and increased risk of complex sleep behaviors. 3
Next-day residual effects: While clinical trials showed minimal next-day effects at 8 hours post-dose, real-world data indicates 15% of adults on 12.5 mg and 6% of elderly on 6.25 mg report next-day somnolence. 3
Special Considerations for Elderly
Pharmacokinetic differences in older adults necessitate dose reduction:
Elderly patients (≥65 years) demonstrate altered drug metabolism with mean elimination half-life of 2.9 hours (range 1.59-5.50 hours) compared to younger adults. 3
The recommended dose for elderly patients is 6.25 mg (half the adult dose of 12.5 mg) due to these pharmacokinetic changes. 3
Clinical Context
The 2019 Beers Criteria update maintained the recommendation to avoid nonbenzodiazepine hypnotics despite their historical perception as "safer" alternatives to traditional benzodiazepines. 4 Recent evidence has revealed similar negative effects between Z-drugs and benzodiazepines in older populations. 4
Common pitfall: Clinicians may mistakenly believe Z-drugs are exempt from Beers Criteria concerns because they are "non-benzodiazepines"—this is incorrect, as they share similar risks and are explicitly included. 2, 4
Alternative Approaches
When insomnia treatment is necessary in elderly patients, cognitive behavioral therapy for insomnia (CBT-I) represents the first-line treatment of choice. 5 For patients already on zolpidem, gradual discontinuation with dose reductions of 10-25% per week is recommended, potentially facilitated by CBT-I or alternative agents like melatonin 2 mg prolonged-release. 5